Enhancement of Endothelial Progenitor Cell Numbers and Migration by H1152, a Rho Kinase Specific Inhibitor | Zendy

O Eunju | Zendy; Seung Woo Lee | Zendy; Hyun-Sun Lee | Zendy; Hee-Suk Lim | Zendy; Hyunyoung Ahn | Zendy; JongChul Shin | Zendy; Yonggoo Kim | Zendy; Young Ae Joe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Enhancement of Endothelial Progenitor Cell Numbers and Migration by H1152, a Rho Kinase Specific Inhibitor

Author(s) -

O Eunju,

Seung Woo Lee,

Hyun-Sun Lee,

Hee-Suk Lim,

Hyunyoung Ahn,

JongChul Shin,

Yonggoo Kim,

Young Ae Joe

Publication year - 2012

Publication title -

bioscience biotechnology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.509

H-Index - 116

eISSN - 1347-6947

pISSN - 0916-8451

DOI - 10.1271/bbb.110468

Subject(s) - progenitor cell , ex vivo , endothelial progenitor cell , progenitor , protein kinase b , in vivo , cancer research , microbiology and biotechnology , endothelial stem cell , phosphorylation , chemistry , cord blood , stem cell , medicine , biology , in vitro , biochemistry

Endothelial progenitor cells (EPCs) are applied in the treatment of ischemic diseases. In ex vivo culture of human cord-blood derived EPCs, H1152, (S)-(+)-2-methyl-1-[(4-methyl-5-iso-quinolinyl) sulfonyl]-homopiperazine, markedly increased the number of EPCs. It also induced EPC migration, stimulated the phosphorylation of AKT, and reduced the expression of p27 in the EPCs. Thus H1152 can be used effectively in ex vivo expansion of EPCs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research